Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # Check out FDAs new roster of bulk drug substances being pulled from use in compounding. Youll see BPC 157 and TB 500 among the various peptides added to the list of category 2 substances The peptide conversation is shifting. Secretary RFK Jr. recently announced that the FDA plans to move 14 peptides from Category 2 back to Category 1 restoring FDA recognized status and making them Updates on 503A Compounding: Legal and Regulatory Developments Pharmacy Times